Camp4 Therapeutics Corp (CAMP) Form 10-Q — Aug 13, 2026
CAMP4 Therapeutics reported a Q2 2026 net loss of $33.5 million, more than double the $12.6 million loss a year earlier, driven primarily by a $20.9 million non-cash charge from the change in fair value of its derivative tranche liability. Research and collaboration revenue rose to $1.8 million from $1.5 million, largely tied to the December 2025 GSK collaboration. The balance sheet showed $86.4 million in cash as of June 30, 2026, with stockholders' equity turning negative at $0.7 million due to a $71.9 million derivative tranche liability, against a $344.0 million accumulated deficit. Operating cash burn was $23.7 million for the first half of 2026.
Key figures
- Revenue
- 1779000
- Guidance
- Cash and equivalents plus $46.9M Second Closing net proceeds expected to fund operating expenses and capital expenditures through end of 2028; Phase 1/2 CMP-002 trial initiation planned Q4 2026
- Revenue Yoy
- +18.8% Q2 YoY ($1.8M vs $1.5M); +30.5% 1H YoY ($3.1M vs $2.4M)
- Total Assets
- 93428000
- Cash Position
- 86398000
- Shares Outstanding
- 62753200
- Working capital
- 70900000
- Six month revenue
- 3073000
- Accumulated deficit
- 344017000
- Gsk upfront payment
- 17500000
- G and a expense q2 2026
- 4342000
- R and d expense q2 2026
- 10817000
- Gsk potential milestones
- 440000000
- Shelf registration capacity
- 300000000
- Atm sales agreement capacity
- 100000000
- Derivative tranche liability
- 71878000
- Syngap1 patient population estimate
- 21000
- Second closing net proceeds aug 2026
- 46900000
- Second closing gross proceeds aug 2026
- 50100000
Price after filing
Close on the filing date to close N calendar days later (from $4.50). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.